The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastaglio, Sara, Ruggeri, Annalisa, Risitano, Antonio M., Angelillo, Piera, Yancopoulou, Despina, Mastellos, Dimitrios C., Huber-Lang, Markus, Piemontese, Simona, Assanelli, Andrea, Garlanda, Cecilia, Lambris, John D., Ciceri, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189192/
https://www.ncbi.nlm.nih.gov/pubmed/32360516
http://dx.doi.org/10.1016/j.clim.2020.108450
_version_ 1783527453490151424
author Mastaglio, Sara
Ruggeri, Annalisa
Risitano, Antonio M.
Angelillo, Piera
Yancopoulou, Despina
Mastellos, Dimitrios C.
Huber-Lang, Markus
Piemontese, Simona
Assanelli, Andrea
Garlanda, Cecilia
Lambris, John D.
Ciceri, Fabio
author_facet Mastaglio, Sara
Ruggeri, Annalisa
Risitano, Antonio M.
Angelillo, Piera
Yancopoulou, Despina
Mastellos, Dimitrios C.
Huber-Lang, Markus
Piemontese, Simona
Assanelli, Andrea
Garlanda, Cecilia
Lambris, John D.
Ciceri, Fabio
author_sort Mastaglio, Sara
collection PubMed
description Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101.
format Online
Article
Text
id pubmed-7189192
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71891922020-04-29 The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 Mastaglio, Sara Ruggeri, Annalisa Risitano, Antonio M. Angelillo, Piera Yancopoulou, Despina Mastellos, Dimitrios C. Huber-Lang, Markus Piemontese, Simona Assanelli, Andrea Garlanda, Cecilia Lambris, John D. Ciceri, Fabio Clin Immunol Article Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101. Elsevier Inc. 2020-06 2020-04-29 /pmc/articles/PMC7189192/ /pubmed/32360516 http://dx.doi.org/10.1016/j.clim.2020.108450 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mastaglio, Sara
Ruggeri, Annalisa
Risitano, Antonio M.
Angelillo, Piera
Yancopoulou, Despina
Mastellos, Dimitrios C.
Huber-Lang, Markus
Piemontese, Simona
Assanelli, Andrea
Garlanda, Cecilia
Lambris, John D.
Ciceri, Fabio
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
title The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
title_full The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
title_fullStr The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
title_full_unstemmed The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
title_short The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
title_sort first case of covid-19 treated with the complement c3 inhibitor amy-101
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189192/
https://www.ncbi.nlm.nih.gov/pubmed/32360516
http://dx.doi.org/10.1016/j.clim.2020.108450
work_keys_str_mv AT mastagliosara thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT ruggeriannalisa thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT risitanoantoniom thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT angelillopiera thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT yancopouloudespina thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT mastellosdimitriosc thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT huberlangmarkus thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT piemontesesimona thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT assanelliandrea thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT garlandacecilia thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT lambrisjohnd thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT cicerifabio thefirstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT mastagliosara firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT ruggeriannalisa firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT risitanoantoniom firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT angelillopiera firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT yancopouloudespina firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT mastellosdimitriosc firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT huberlangmarkus firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT piemontesesimona firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT assanelliandrea firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT garlandacecilia firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT lambrisjohnd firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101
AT cicerifabio firstcaseofcovid19treatedwiththecomplementc3inhibitoramy101

Ejemplares similares